We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
(-5.9%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$25.4M |
| 2 |
AbbVie
ABBV
|
+$21.9M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.2M |
| 4 |
Waste Management
WM
|
+$19M |
| 5 |
Gilead Sciences
GILD
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$70.2M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$45.8M |
| 3 |
Biogen
BIIB
|
+$43.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$24.8M |
| 5 |
Amgen
AMGN
|
+$21.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.81% |
| 2 | Technology | 18.27% |
| 3 | Financials | 10.05% |
| 4 | Consumer Discretionary | 9.39% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Cencora
COR
$60.3B
| $10.3M | 0.14% |
124,787
+72,092
| +137% | +$6.2M |
|
177
Microchip Technology
MCHP
$42.8B
| $10.2M | 0.14% |
220,158
-198,554
| -47% | -$9M |
|
|
HES
178
DELISTED
Hess
HES
| $10.2M | 0.14% |
168,398
+146,405
| +666% | +$9.12M |
|
179
Ulta Beauty
ULTA
$20.4B
| $10.1M | 0.13% |
40,343
+36,949
| +1,089% | +$11.3M |
|
180
Trex
TREX
$4.51B
| $10M | 0.13% |
220,830
-22,882
| -9% | -$923K |
|
181
Halozyme
HALO
$9.72B
| $10M | 0.13% |
647,079
+37,000
| +6% | +$609K |
|
182
Darden Restaurants
DRI
$22.5B
| $10M | 0.13% |
84,866
-20,634
| -20% | -$2.52M |
|
183
Nutrien
NTR
$32.7B
| $9.88M | 0.13% |
198,156
+161,671
| +443% | +$8.25M |
|
184
Target
TGT
$62.1B
| $9.76M | 0.13% |
91,298
+43,998
| +93% | +$4.19M |
|
185
eBay
EBAY
$48.6B
| $9.7M | 0.13% |
248,785
+106,089
| +74% | +$4.26M |
|
186
Entergy
ETR
$54.1B
| $9.65M | 0.13% |
164,404
-3,700
| -2% | -$202K |
|
187
MacroGenics
MGNX
$235M
| $9.63M | 0.13% |
754,988
+4,000
| +0.5% | +$57.6K |
|
188
Motorola Solutions
MSI
$69.4B
| $9.58M | 0.13% |
56,202
+16,169
| +40% | +$2.78M |
|
|
MRTX
189
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $9.53M | 0.13% |
122,300
-34,700
| -22% | -$3.26M |
|
190
CVS Health
CVS
$137B
| $9.51M | 0.13% |
150,698
+35,533
| +31% | +$2.11M |
|
191
RTX Corp
RTX
$287B
| $9.49M | 0.13% |
110,517
+19,108
| +21% | +$1.59M |
|
192
Best Buy
BBY
$18B
| $9.4M | 0.12% |
136,259
+35,888
| +36% | +$2.5M |
|
|
AMRN
193
Amarin Corp
AMRN
$284M
| $9.4M | 0.12% |
+31,000
| New | +$10.8M |
|
194
Toronto Dominion Bank
TD
$198B
| $9.32M | 0.12% |
159,798
-6,678
| -4% | -$380K |
|
195
Ameriprise Financial
AMP
$46.8B
| $9.22M | 0.12% |
62,651
-3,127
| -5% | -$438K |
|
196
Lincoln National
LNC
$7.91B
| $9.08M | 0.12% |
150,559
-6,914
| -4% | -$413K |
|
197
Akamai
AKAM
$16.8B
| $9.07M | 0.12% |
99,232
-14,859
| -13% | -$1.29M |
|
198
Ascendis Pharma A/S
ASND
$16.7B
| $9.05M | 0.12% |
+94,000
| New | +$10.5M |
|
199
CDW
CDW
$17.1B
| $9.01M | 0.12% |
73,124
+52,977
| +263% | +$6.08M |
|
200
Fidelity National Information Services
FIS
$21.5B
| $8.96M | 0.12% |
67,514
+23,720
| +54% | +$3.15M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2019 Portfolio in Review
As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.
- Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
- Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
- Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
- Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
- Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
- Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
- Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.
Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.